GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Nexturnbioscience Co Ltd (XKRX:089140) » Definitions » EBIT

Nexturnbioscience Co (XKRX:089140) EBIT : ₩20,537 Mil (TTM As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Nexturnbioscience Co EBIT?

Nexturnbioscience Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ₩2,073 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩20,537 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nexturnbioscience Co's annualized ROC % for the quarter that ended in Mar. 2024 was -1.25%. Nexturnbioscience Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 29.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nexturnbioscience Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 25.10%.


Nexturnbioscience Co EBIT Historical Data

The historical data trend for Nexturnbioscience Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexturnbioscience Co EBIT Chart

Nexturnbioscience Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,919.54 -3,429.00 -1,581.56 1,028.19 20,999.05

Nexturnbioscience Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,548.94 40,262.27 1,590.76 -23,388.95 2,073.09

Competitive Comparison of Nexturnbioscience Co's EBIT

For the Specialty Industrial Machinery subindustry, Nexturnbioscience Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexturnbioscience Co's EV-to-EBIT Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Nexturnbioscience Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nexturnbioscience Co's EV-to-EBIT falls into.



Nexturnbioscience Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩20,537 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nexturnbioscience Co  (XKRX:089140) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nexturnbioscience Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-4109.736 * ( 1 - 13.23% )/( (283894.663 + 287972.232)/ 2 )
=-3566.0179272/285933.4475
=-1.25 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=243994.294 - 6994.527 - ( 31140.685 - max(0, 93672.16 - 46777.264+31140.685))
=283894.663

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=252307.36 - 7055.338 - ( 36523.611 - max(0, 97643.003 - 54922.793+36523.611))
=287972.232

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Nexturnbioscience Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=8292.372/( ( (27955.493 + max(-4003.966, 0)) + (27652.004 + max(-178.98699999999, 0)) )/ 2 )
=8292.372/( ( 27955.493 + 27652.004 )/ 2 )
=8292.372/27803.7485
=29.82 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6713.42 + 6247.312 + 688.055) - (6994.527 + 0 + 10658.226)
=-4003.966

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4375.609 + 8442.985 + 589.855) - (7055.338 + 0 + 6532.098)
=-178.98699999999

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nexturnbioscience Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=20537.169/81805.592
=25.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nexturnbioscience Co EBIT Related Terms

Thank you for viewing the detailed overview of Nexturnbioscience Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexturnbioscience Co (XKRX:089140) Business Description

Traded in Other Exchanges
N/A
Address
35, Giheungdanzi-ro 121beon-gil, Giheung-gu, Gyeonggi-do, Youngin-si, KOR, 446-901
Nexturnbioscience Co Ltd, formerly NEXTURN Co Ltd makes and sells automatic lathes. The company offers the main spindle moving CNC large automatic lathe, the main spindle fixed large automatic lathe. Its products include CNC Swiss-type Automatic Lathe; High-Temperature Display Glass Press; and Automatic Line-up Robot.

Nexturnbioscience Co (XKRX:089140) Headlines

No Headlines